229 related articles for article (PubMed ID: 30726104)
21. Inhibition of CDK9 attenuates atherosclerosis by inhibiting inflammation and phenotypic switching of vascular smooth muscle cells.
Huang S; Luo W; Wu G; Shen Q; Zhuang Z; Yang D; Qian J; Hu X; Cai Y; Chattipakorn N; Huang W; Liang G
Aging (Albany NY); 2021 Jun; 13(11):14892-14909. PubMed ID: 34102609
[TBL] [Abstract][Full Text] [Related]
22. ASF1B promotes cervical cancer progression through stabilization of CDK9.
Liu X; Song J; Zhang Y; Wang H; Sun H; Feng X; Hou M; Chen G; Tang Q; Ji M
Cell Death Dis; 2020 Aug; 11(8):705. PubMed ID: 32848135
[TBL] [Abstract][Full Text] [Related]
23. Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells.
Kumar S; Bryant CS; Chamala S; Qazi A; Seward S; Pal J; Steffes CP; Weaver DW; Morris R; Malone JM; Shammas MA; Prasad M; Batchu RB
Mol Cancer; 2009 Apr; 8():26. PubMed ID: 19386116
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-613 inhibits the progression of gastric cancer by targeting CDK9.
Lu Y; Tang L; Zhang Q; Zhang Z; Wei W
Artif Cells Nanomed Biotechnol; 2018 Aug; 46(5):980-984. PubMed ID: 28701053
[TBL] [Abstract][Full Text] [Related]
25. Molecular Insights on Selective and Specific Inhibitors of Cyclin Dependent Kinase 9 Enzyme (CDK9) for the Purpose of Cancer Therapy.
Karati D; Mahadik KSR; Trivedi P; Kumar D
Anticancer Agents Med Chem; 2023; 23(4):383-403. PubMed ID: 35708082
[TBL] [Abstract][Full Text] [Related]
26. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1.
Lemke J; von Karstedt S; Abd El Hay M; Conti A; Arce F; Montinaro A; Papenfuss K; El-Bahrawy MA; Walczak H
Cell Death Differ; 2014 Mar; 21(3):491-502. PubMed ID: 24362439
[TBL] [Abstract][Full Text] [Related]
27. Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer.
Zhang H; Pandey S; Travers M; Sun H; Morton G; Madzo J; Chung W; Khowsathit J; Perez-Leal O; Barrero CA; Merali C; Okamoto Y; Sato T; Pan J; Garriga J; Bhanu NV; Simithy J; Patel B; Huang J; Raynal NJ; Garcia BA; Jacobson MA; Kadoch C; Merali S; Zhang Y; Childers W; Abou-Gharbia M; Karanicolas J; Baylin SB; Zahnow CA; Jelinek J; Graña X; Issa JJ
Cell; 2018 Nov; 175(5):1244-1258.e26. PubMed ID: 30454645
[TBL] [Abstract][Full Text] [Related]
28. The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression.
Hou T; Ray S; Brasier AR
J Biol Chem; 2007 Dec; 282(51):37091-102. PubMed ID: 17956865
[TBL] [Abstract][Full Text] [Related]
29. CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation.
Gordon V; Bhadel S; Wunderlich W; Zhang J; Ficarro SB; Mollah SA; Shabanowitz J; Hunt DF; Xenarios I; Hahn WC; Conaway M; Carey MF; Gioeli D
Mol Endocrinol; 2010 Dec; 24(12):2267-80. PubMed ID: 20980437
[TBL] [Abstract][Full Text] [Related]
30. Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer.
Ma Z; Wang X; He J; Xia J; Li Y
PLoS One; 2017; 12(3):e0174037. PubMed ID: 28355289
[TBL] [Abstract][Full Text] [Related]
31. Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer.
Hernandez L; Hsu SC; Davidson B; Birrer MJ; Kohn EC; Annunziata CM
Cancer Res; 2010 May; 70(10):4005-14. PubMed ID: 20424119
[TBL] [Abstract][Full Text] [Related]
32. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma.
Huang CH; Lujambio A; Zuber J; Tschaharganeh DF; Doran MG; Evans MJ; Kitzing T; Zhu N; de Stanchina E; Sawyers CL; Armstrong SA; Lewis JS; Sherr CJ; Lowe SW
Genes Dev; 2014 Aug; 28(16):1800-14. PubMed ID: 25128497
[TBL] [Abstract][Full Text] [Related]
33. Cyclin-dependent kinase 9 activity regulates neutrophil spontaneous apoptosis.
Wang K; Hampson P; Hazeldine J; Krystof V; Strnad M; Pechan P; M J
PLoS One; 2012; 7(1):e30128. PubMed ID: 22276149
[TBL] [Abstract][Full Text] [Related]
34. The CDK9-cyclin T1 complex mediates saturated fatty acid-induced vascular calcification by inducing expression of the transcription factor CHOP.
Shiozaki Y; Okamura K; Kohno S; Keenan AL; Williams K; Zhao X; Chick WS; Miyazaki-Anzai S; Miyazaki M
J Biol Chem; 2018 Nov; 293(44):17008-17020. PubMed ID: 30209133
[TBL] [Abstract][Full Text] [Related]
35. Correlation of CD44v6 expression with ovarian cancer progression and recurrence.
Shi J; Zhou Z; Di W; Li N
BMC Cancer; 2013 Apr; 13():182. PubMed ID: 23565736
[TBL] [Abstract][Full Text] [Related]
36. CDK9 inhibition strategy defines distinct sets of target genes.
Garriga J; Graña X
BMC Res Notes; 2014 May; 7():301. PubMed ID: 24886624
[TBL] [Abstract][Full Text] [Related]
37. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma.
Tong Z; Chatterjee D; Deng D; Veeranki O; Mejia A; Ajani JA; Hofstetter W; Lin S; Guha S; Kopetz S; Krishnan S; Maru D
Oncotarget; 2017 Apr; 8(17):28696-28710. PubMed ID: 28404924
[TBL] [Abstract][Full Text] [Related]
38. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
39. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
40. Cell cycle-related kinase supports ovarian carcinoma cell proliferation via regulation of cyclin D1 and is a predictor of outcome in patients with ovarian carcinoma.
Wu GQ; Xie D; Yang GF; Liao YJ; Mai SJ; Deng HX; Sze J; Guan XY; Zeng YX; Lin MC; Kung HF
Int J Cancer; 2009 Dec; 125(11):2631-42. PubMed ID: 19672860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
